遗传性弥漫性胃癌
本文综述遗传性弥漫性胃癌(HDGC)的遗传学、临床表型变异、病理、肿瘤起始机制与自然史,并描述当前最佳临床管理实践,包括新兴基因检测标准、内镜监测方法、预防性手术并发症、术后生活质量及新兴化学预防领域。
要点
- HDGC为常染色体显性遗传肿瘤综合征,特征为弥漫性胃癌和小叶乳腺癌高发。
- HDGC由参与上皮黏附连接复合物的CDH1和CTNNA1基因种系突变引起。
- 临床管理涵盖新兴基因检测标准、内镜监测、预防性手术并发症、术后生活质量及化学预防。
核心结论
- 本文综述HDGC的遗传学、临床表型变异、病理、肿瘤起始机制与自然史,并描述当前最佳临床管理实践。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- HDGC为常染色体显性遗传肿瘤综合征,特征为弥漫性胃癌和小叶乳腺癌高发。
- HDGC由CDH1和CTNNA1基因种系突变引起,两基因均参与上皮黏附连接复合物。
- HDGC的临床表型存在变异,晚期弥漫性胃癌和小叶乳腺癌的外显率在家族内和家族间均可变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary diffuse gastric cancer (HDGC) is a dominantly inherited cancer syndrome characterized by a high incidence of diffuse gastric cancer (DGC) and lobular breast cancer (LBC). HDGC is caused by germline mutations in 2 genes involved in the epithelial adherens junction complex, CDH1 and CTNNA1. We discuss the genetics of HDGC and the variability of its clinical phenotype, in particular the variable penetrance of advanced DGC and LBC, both within and between families. We review the pathology of the disease, the mechanism of tumor initiation, and its natural history. Finally, we describe current best practice for the clinical management of HDGC, including emerging genetic testing criteria for the identification of new families, methods for endoscopic surveillance, the complications associated with prophylactic surgery, postoperative quality of life, and the emerging field of HDGC chemoprevention.
引用
- Decourtye-Espiard L, Guilford P. Hereditary Diffuse Gastric Cancer. Gastroenterology. 2023. PMID: 36740198. doi:10.1053/j.gastro.2023.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。